Combo Therapy May Help Those Whose Prostate Cancer Recurs After Gland Removed

Combo Therapy May Help Those Whose Prostate Cancer Recurs After Gland Removed
Men who show biochemical signs that their prostate cancer is recurring after removal of their prostate may live years longer from a combination of hormone and radiation therapy, a Phase 3 trial suggests. The combination can reduce the rate of prostate cancer metastasis -- or the cancer spreading to other organs -- compared with radiation therapy alone, and without major side effects, the study showed. The research, "Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer," was published in The New England Journal of Medicine. Many patients with prostate cancer are treated with radical prostatectomy, or removal of the prostate. But more than 30 percent see the disease return one to four years after the surgery. Doctors usually recommend radiation therapy for these patients, but the disease will progress in nearly half of them. The NRG Oncology's Radiation Therapy Oncology Group (RTOG) designed a randomized, double-blind, placebo-controlled RTOG 9601 trial (NCT00002874) of the combo treatment. The question was whether adding antiandrogen therapy for 24 months during and after radiation therapy could prolong patients' overall survival rate, compared with radiation therapy plus placebo. The study included 761 prostate cancer patients from 17 medical institutions in the United States and Canada. They were randomized to receive the androgen receptor blocker Casodex (bicalutamide) or a placebo every day for two years in combination with seven weeks of radiation therapy
Subscribe or to access all post and page content.

One comment

  1. Gharati says:

    Hi dr. I am 70 year old I was down prostatic surgery pelvic radiation plus Ati androgen for 3 years 9years ago .psa raised since 1year ago from0.2 to 0.6 it is my question now what’s the best yours opinion With best regards.

Leave a Comment

Your email address will not be published. Required fields are marked *